Label: SIMPLICEF- cefpodoxime proxetil tablet 

  • Label RSS
  • NDC Code(s): 54771-5228-1, 54771-5228-2, 54771-5229-1, 54771-5229-2
  • Packager: Zoetis Inc.
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated 03/14

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    For Oral Use In Dogs Only

    Close
  • SPL UNCLASSIFIED SECTION

    CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

    Close
  • DESCRIPTION

    Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic cephalosporin antibiotic. The chemical name is: (+/-)-1-Hydroxyethyl(+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl) glyoxylamido]-3-methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 72-(Z)-(Omethyloxime), isopropyl carbonate (ester) [87239-81-4].

    Cefpodoxime proxetil Chemical Structure:

    Chemical Structure

    Cefpodoxime proxetil is a prodrug; its active metabolite is cefpodoxime. All doses of SIMPLICEF (cefpodoxime proxetil) tablets are expressed in terms of the active cefpodoxime moiety. SIMPLICEF is available as:

    100 mg Tablet, each reddish-orange, elliptical, scored tablet contains cefpodoxime proxetil equivalent to 100 mg of cefpodoxime.

    200 mg Tablet, each light orange, round rectangle, scored tablet contains cefpodoxime proxetil equivalent to 200 mg of cefpodoxime.

    Close
  • INDICATION

    SIMPLICEF tablets are indicated for the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, β hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

    Close
  • DOSAGE AND ADMINISTRATION

    Dose range: The dose range of SIMPLICEF (cefpodoxime proxetil) tablets is 5-10 mg/kg (2.3-4.5 mg/lb) body weight, administered orally, once a day. The dose may be given with or without food. The determination of dosage for any particular patient must take into consideration such factors as the severity and nature of the infection, the susceptibility of the causative organisms, and the integrity of the patient's host-defense mechanisms. Obtain a sample of the pathogenic organism for culture and sensitivity testing prior to beginning antimicrobial therapy. Once results become available, continue with appropriate therapy.

    Duration: SIMPLICEF tablets should be administered once daily for 5-7 days or for 2-3 days beyond the cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen.

    Dosing Charts: For daily oral administration of SIMPLICEF at 5 mg/kg (Table 1) and 10 mg/kg (Table 2).

    Table 1. Dose Table for SIMPLICEF Tablets at 5 mg/kg Total Daily Dosage
    Weight of Dog (lbs)
    Daily Dose 22 44 66 88 132
    No. of 100 mg tablets 0.5 1 1.5 1
    No. of 200 mg tablets 1 1
    Weight of Dog (kgs)
    Daily Dose 10 20 30 40 60
    No. of 100 mg tablets 0.5 1 1.5 1
    No. of 200 mg tablets 1 1
    Table 2. Dose Table for SIMPLICEF Tablets at 10 mg/kg Total Daily Dosage
    Weight of Dog (lbs)
    Daily Dose 11 22 44 66 88 132
    No. of 100 mg tablets 0.5 1 1
    No. of 200 mg tablets 1 1 2 3
    Weight of Dog (kgs)
    Daily Dose 5 10 20 30 40 60
    No. of 100 mg tablets 0.5 1 1
    No. of 200 mg tablets 1 1 2 3
    Close
  • CONTRAINDICATIONS

    Cefpodoxime proxetil is contraindicated in dogs with known allergy to cefpodoxime or to the β-lactam (penicillins and cephalosporins) group of antibiotics.

    Close
  • WARNINGS

    Not for human use. Keep this and all drugs out of reach of children. Antimicrobial drugs, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. To minimize the possibility of allergic reactions, those handling such antimicrobials, including cefpodoxime, are advised to avoid direct contact of the product with the skin and mucous membranes.

    Close
  • PRECAUTIONS

    The safety of cefpodoxime proxetil in dogs used for breeding, pregnant dogs, or lactating bitches has not been demonstrated. As with other cephalosporins, cefpodoxime proxetil may occasionally induce a positive direct Coombs' test.

    Close
  • ADVERSE REACTIONS

    A total of 216 dogs of various breeds and ages ranging from 2 months to 15 years were included in the field study safety analysis. The following table shows the number of dogs displaying each clinical observation.

    Table 3. Abnormal Health Findings in the U.S. Field Study*
    Clinical Observation SIMPLICEF
    (n=118)
    Active Control (n=98)
    *
    Dogs may have experienced more than one of the observations during the study.
    Vomiting 2 4
    Diarrhea 1 1
    Increased water drinking 0 2
    Decreased appetite 1 1

    To report a suspected adverse reaction call 1-888-963-8471.

    To request a material safety data sheet (MSDS) for SIMPLICEF tablets, call 1-888-963-8471.

    Close
  • CLINICAL PHARMACOLOGY

    Pharmacokinetics/Pharmacodynamics: Cefpodoxime proxetil is a prodrug that is absorbed from and de-esterified in the gastrointestinal tract to its active metabolite, cefpodoxime. Following oral administration to fasting Beagles, oral bioavailability was 63.1 ± 5.3%.

    Figure 1. Canine Plasma Concentration of Cefpodoxime After a Single Oral Dose of 10 mg/kg Cefpodoxime Proxetil Tablets

    Graph

    Cefpodoxime is distributed in the body with an apparent volume of distribution of 151 ± 27 mL/kg. Like other β-lactam antibiotics, cefpodoxime is eliminated from the body primarily in the urine, with an apparent elimination half-life of approximately 5-6 hours after oral administration. This is similar to the 4.7 hour apparent elimination half-life observed after intravenous dosing. Following intravenous administration of 10 mg/kg, the average total body clearance (ClB) was 22.7 ± 4.19 mL/hr/kg.

    Table 4. Summary of Pharmacokinetic Parameters Obtained after a Single Oral Dose of 10 mg Cefpodoxime/kg BW, Administered as a Tablet
    PK Parameter Unit Tablet (SD)
    AUC0-∞ mcg∙hr/mL 145 (77.6)
    AUC0-LOQ mcg∙hr/mL 142 (77.5)
    Maximum concentration (Cmax) mcg/mL 16.4 (11.8)
    Terminal plasma elimination half-life (t1/2,z) hr 5.61 (1.15)
    Time of maximum concentration (tmax) hr 2.21 (0.542)
    Mean residence time (MRT0-∞) hr 9.21 (1.97)

    Microbiology: Like other β-lactam antibiotics, cefpodoxime exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalently binding to the penicillin-binding proteins (PBPs) (i.e. transpeptidase and/or carboxypeptidase), which are essential for synthesis of the bacterial cell wall. Therefore, cefpodoxime is bactericidal. Cefpodoxime is stable in the presence of many common β-lactamase enzymes. As a result, many organisms resistant to other β-lactam antibiotics (penicillins and some cephalosporins) due to the production of β-lactamases may be susceptible to cefpodoxime.

    Cefpodoxime has a broad spectrum of clinically useful antibacterial activity that includes staphylococci, streptococci, and Gram-negative species (including Pasteurella, Escherichia, and Proteus). The compound is not active against most obligate anaerobes, Pseudomonas spp., or enterococci. The minimum inhibitory concentrations (MICs) for cefpodoxime against Gram-positive and Gram-negative pathogens isolated from canine skin infections (wounds and abscesses) in a 2002 U.S. field study are presented in Table 5. All MICs were determined in accordance with the National Committee for Clinical Laboratory Standards (NCCLS). Appropriate quality control (QC) ranges for in vitro susceptibility testing are presented in Table 6.

    Table 5. Cefpodoxime Minimum Inhibitory Concentration Values (mcg/mL) from a 2002 Field Study Evaluating Skin Infections (wounds and abscesses) of Canines in the United States.
    Organism* # of Isolates MIC50 MIC90 Range
    *
    Veterinary specific interpretive criteria have not been established for the above listed canine pathogens by the NCCLS at this time.
    No Range, all isolates yielded the same value.
    Staphylococcus intermedius 118 0.12 0.50 0.12->32.0
    Streptococcus canis (group G, β hemolytic) 33 ≤0.03 ≤0.03 ≤0.03
    Escherichia coli 41 0.25 0.50 0.12->32.0
    Pasteurella multocida 32 ≤0.03 ≤0.03 ≤0.03-0.12
    Proteus mirabilis 14 ≤0.03 0.06 ≤0.03-0.06
    Staphylococcus aureus 19 2.0 2.0 0.12-2.0
    Table 6. Acceptable Quality Control Ranges for Cefpodoxime
    QC ATCC strain KB Disk Diffusion Method Broth Micro-dilution Method
    Drug concentration Zone diameter MIC
    *
    These ranges are for quality control strains used to monitor accuracy of minimum inhibitory concentrations (MICs) of non-fastidious organisms using cation-adjusted Mueller-Hinton agar or broth medium. The dilution range should encompass the QC ranges of these strains in the broth micro-dilution method.
    These ranges are for quality control strains used to monitor accuracy of minimum inhibitory concentrations (MICs) of fastidious organisms. When susceptibility testing is performed for Streptococcus canis (group G, β hemolytic), Streptococcus pneumoniae ATCC 49619 should be included as a QC strain in the presence of 5% lysed sheep blood (KB disk diffusion method) or 2.5% lysed horse blood (broth micro-dilution method).
    Escherichia coli 25922 10 mcg 23-28 mm* 0.25-1 mcg/mL*
    Staphylococcus aureus 25923 10 mcg 19-25 mm*
    Staphylococcus aureus 29213 1-8 mcg/mL*
    Streptococcus pneumoniae 49619 10 mcg 28-34 mm 0.03-0.12 mcg/mL
    Close
  • EFFECTIVENESS

    The clinical effectiveness of SIMPLICEF (cefpodoxime proxetil) was established in a multi-location (23 site) field study. In this study, 216 dogs with infected wounds or abscesses were treated with either SIMPLICEF (n=118) once daily at 5 mg/kg (2.3 mg/lb) body weight or with a active control antibiotic (n=98) administered twice daily for 5-7 days. In this study, SIMPLICEF was considered noninferior to the active control (88.7% versus 88.4% respectfully) in the treatment of canine skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, β hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

    Close
  • ANIMAL SAFETY

    In target animal safety studies, cefpodoxime was well tolerated at exaggerated daily oral doses of 100 mg/kg/day (10 times the maximum label dose) for 13 weeks in adult dogs and for 28 days in puppies (18- 23 days of age). Therefore, once daily administration of cefpodoxime oral tablets at the maximum labeled dose of 10 mg/kg for up to 28 days was shown to be safe in adult dogs and puppies.

    Blood dyscrasia including neutropenias, may be seen following high doses of cephalosporins. Cephalosporin administration should be discontinued in such cases.

    Close
  • STORAGE INFORMATION

    Store tablets at controlled room temperature 20° to 25°C (68° to 77°F). Replace cap securely after each opening.

    Close
  • HOW SUPPLIED

    SIMPLICEF tablets are available in the following strengths (cefpodoxime equivalent), colors, and sizes:

    100 mg (reddish-orange, elliptical, scored, debossed with 5228)

    Bottles of 100
    Bottles of 250

    200 mg (light orange, round rectangle, scored, debossed with 5229)

    Bottles of 100
    Bottles of 250

    Close
  • SPL UNCLASSIFIED SECTION

    NADA # 141-232, Approved by FDA

    Manufactured by:
    Sandoz
    Kundl, Austria

    Product of India

    Distributed by:
    Zoetis Inc.
    Kalamazoo, MI 49007

    Revised June 2013

    46104787

    Close
  • PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label

    SIMPLICEF®
    (cefpodoxime proxetil)

    100 mg

    100 TABLETS

    Antimicrobial For Oral Use
    in Dogs Only

    Caution: Federal (USA) law
    restricts this drug to use by
    or on the order of a licensed
    veterinarian.

    NADA# 141-232, Approved by FDA

    zoetis

    PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label
    Close
  • PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label

    SIMPLICEF®
    (cefpodoxime proxetil)

    200 mg

    100 TABLETS

    Antimicrobial For Oral Use
    in Dogs Only

    Caution: Federal (USA) law
    restricts this drug to use by
    or on the order of a licensed
    veterinarian.

    NADA# 141-232, Approved by FDA

    zoetis

    PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label
    Close
  • INGREDIENTS AND APPEARANCE
    SIMPLICEF 
    cefpodoxime proxetil tablet
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:54771-5228
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    cefpodoxime proxetil (cefpodoxime) cefpodoxime 100 mg
    Product Characteristics
    Color ORANGE (reddish-orange) Score 2 pieces
    Shape OVAL (elliptical) Size 11mm
    Flavor Imprint Code 5228
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:54771-5228-1 100 in 1 BOTTLE
    2 NDC:54771-5228-2 250 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA141232 07/22/2004
    SIMPLICEF 
    cefpodoxime proxetil tablet
    Product Information
    Product Type PRESCRIPTION ANIMAL DRUG LABEL Item Code (Source) NDC:54771-5229
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    cefpodoxime proxetil (cefpodoxime) cefpodoxime 200 mg
    Product Characteristics
    Color ORANGE (reddish-orange) Score 2 pieces
    Shape OVAL (elliptical) Size 15mm
    Flavor Imprint Code 5228
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:54771-5229-1 100 in 1 BOTTLE
    2 NDC:54771-5229-2 250 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NADA NADA141232 07/22/2004
    Labeler - Zoetis Inc. (828851555)
    Establishment
    Name Address ID/FEI Business Operations
    Sandoz GmbH 300220969 MANUFACTURE
    Establishment
    Name Address ID/FEI Business Operations
    Sandoz Private Limited 676190116 API MANUFACTURE
    Close